Mode of Action of Ticlopidine in Inhibition of Platelet Aggregation in the Rat

Summary

Ticlopidine, when orally administered to rats, resulted in activation of basal and prostaglandin E¹ (PGE¹)-stimulated adenylate cylase activity through increase in affinity of the cyclase in platelet membrane to PGE¹, although it failed to affect adenosine- or sodium fluoride-stimulated activity of the enzyme. In washed platelets, Ticlopidine also activated basal and PGE¹-stimulated activity of the cyclase and prevented reduction in the cyclase activity caused by low concentrations of PGE². Furthermore, Ticlopidine inhibited malondialdehyde formation in platelets induced by thrombin but failed to inhibit that caused by exogenous arachidonic acid. Adenosine 3’,5’-cyclic monophosphate (c-AMP): phosphodiesterase activity of platelet lysate was not significantly affected by Ticlopidine treatment.

These findings indicate that Ticlopidine inhibits platelet aggregation and prostaglandin synthesis from endogenous substrate through activating basal and PGE₁-stimulated activity of the cyclase, preventing PGE₂-induced depression of the cyclase activity and thus increasing platelet c-AMP level.

• References

• 1 Ashida S, Abiko Y. 1979 Inhibition of platelet aggregation by a new agent, Ticlopidine. Thrombosis and Haemostasis.
• 2 Ashida S, Abiko Y. 1978; Effect of Ticlopidine and acetyl-salicylic acid on generation of prostaglandin I₂-like substance by rat arterial tissue. Thrombosis Research 13: 901
• 3 Ball G, Brereton GG, Fulwood M, Ireland DM, Yates P. 1970; Effect of prostaglandin E₁alone and in combination with theophylline or aspirin on collagen-induced platelet aggregation and on platelet nucleotides including adenosine 3’,5’-cyclic monophosphate. Biochemical Journal 120: 709
• 4 Cole B, Robison GA, Hartmann RC. 1971; Studies on the role of cyclic AMP in platelet function. Annals of the New York Academy of Sciences 185: 327
• 5 Ebihara A, Aoki N, Sano M, Suzuki T. 1977; New antithrombotic drug, Ticlopidine: Phase I study in Japanese. Japanese Journal of Clinical Pharmacology 8: 63
• 6 Flower RJ, Cheung HS, Cushman DW. 1973; Quantitative determination of prostaglandins and malondialdehyde formed by the arachidonate oxygenase (prostaglandin synthetase) system of bovine seminal vesicle. Prostaglandins 4: 325
• 7 Gordon JL, Macintyre DE, Mcmillan RM. Malondialdehyde production and the release reaction in rat blood platelets: inhibition by aspirin and indomethacin ex vivo. In: Abstracts, Proceedings of the British Pharmacological Society. 15.07.1976; 299 p
• 8 Hamberg M, Samuelsson B. 1974; Prostaglandin endoperoxides: Novel transformation of arachidonic acid in human platelets. Proceedings of the National Academy of Science, USA 71: 3400
• 9 Hamberg M, Svensson J, Samuelsson B. 1974; Prostaglandin endoperoxides: A new concept concerning the mode of action and release of prostaglandins. Proceedings of the National Academy of Science, USA 71: 3824
• 10 Haslam RJ, Lynham JA. 1972; Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine. Life Sciences 11: 1143
• 11 Haslam RJ, Rosson GM. 1975; Effect of adenosine on levels of adenosine cyclic 3’,5’-monophosphate in human blood platelets in relation to adenosine incorporation and platelet aggregation. Molecular Pharmacology 11: 528
• 12 Krishna G, Weiss B, Brodie BB. 1968; A simple, sensitive method for the assay of adenylcyclase. Journal of Pharmacology and Experimental Therapeutics 163: 379
• 13 Kunitada S, Honma M, Ui M. 1978; Increases in plasma cyclic AMP dependent on endogenous catecholamines. European Journal of Pharmacology 48: 159
• 14 Lapetina EG, Schmitges CJ, Chandrabose K, Cuatrecasas P. 1977; Cyclic adenosine 3’,5’-monophosphate and prostaglandin inhibit membrane phospholipase activity in platelets. Biochemical and Biophysical Research Communications 76: 828
• 15 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951; Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 193: 265
• 16 Macintyre DE, Gordon JL. 1975; Calcium-dependent stimulation of platelet aggregation by PGE₂ . Nature 258: 337
• 17 Maffrand JP, Eloy F. 1974; Synthesis de thiénopyridine et de furopyridines d’intérêt thérapeutique. European Journal of Medicinal Chemistry 9: 483
• 18 Maguire ME, Sturgill TW, Gilman AG. 1975; Frustration and adenylate cyclase. Metabolism 24: 287
• 19 Malmsten C, Granstrom E, Samuelsson B. 1976; Cyclic AMP inhibits synthesis of prostaglandin endoperoxide (PGG₂) in human platelets. Biochemical and Biophysical Research Communications 68: 569
• 20 Mills DC B, Macfarlane DE. 1974; Stimulation of human platelet adenylate cyclase by prostaglandin D₂ . Thrombosis Research 5: 401
• 21 Mills DC B, Smith JB. 1971; The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3’,5’-cyclic monophosphate in platelets. Biochemical Journal 121: 185
• 22 Minkes M, Stanford N, Chi MM Y, Roth GJ, Raz A, Needleman P, Majerus PW. 1977; Cyclic adenosine 3’,5’-monophosphate inhibits the availability of arachidonate to prostaglandin synthetase in human platelet suspensions. Journal of Clinical Investigation 59: 449
• 23 O’Brien JR. 1968; Effects of salicylates on human platelets. Lancet 1: 779
• 24 Oelz O, Oelz R, Knapp HR, Sweetman BJ, Oates JA. 1977; Biosynthesis of prostaglandin D₂ . 1. Formation of prostaglandin D₂by human platelets Prostaglandins 13: 225
• 25 Podesta M, Aubert D, Ferrand JC. 1974; Contribution à l’étude pharmacologique de thiénopyridines et d’analogues furanniques. European Journal of Medicinal Chemistry 9: 487
• 26 Roth GJ, Stanford N, Majerus PW. 1975; Acetylation of prostaglandin synthetase by aspirin. Proceedings of the National Academy of Science, U.S. A., 72: 3073
• 27 Salzman EW. 1972; Cyclic AMP and platelet function. New England Journal of Medicine 286: 358
• 28 Salzman EW, Kensler PC, Levine L. 1972; Cyclic 3’, 5’-adenosine monophosphate in human blood platelets. IV. Regulatory role of the cyclic AMP in platelet function Annals of the New York Academy of Sciences 201: 61
• 29 Smith JB, Willis AL. 1970; Formation and release of prostaglandin by platelets in response to thrombin. British Journal of Pharmacology 40: 545
• 30 Smith JB, Ingerman C, Kocsis JJ, Silver MJ. 1973; Formation of prostaglandins during the aggregation of human blood platelets. Journal of Clinical Investigation 52: 965
• 31 Smith JB, Ingerman CM, Silver MJ. 1976; Malondialdehyde formation as an indicator of prostaglandin production by human platelets. Journal of Laboratory and Clinical Medicine 88: 167
• 32 Smith JB, Silver MJ, Ingerman CM, Kocsis JJ. 1974; Prostaglandin D₂inhibits the aggregation of human platelets. Thrombosis Research 5: 291
• 33 Stuart MJ, Murphy S, Oski FA. 1975; A simple nonradioisotope technic for the determination of platelet life span. New England Journal of Medicine 2921: 1310
• 34 Thebault JJ, Blatrix CE, Blanchard JF, Panak EA. 1975; Effects of Ticlopidine, a new platelet aggregation inhibitor in man. Clinical Pharmacology and Therapeutics 18: 485
• 35 Villa S, Callioni A, De Gaetano G. 1977; a Normal prostacyclin-like activity in vascular tissues from thrombocytopenic rats. Thrombosis Research 11: 701
• 36 Villa S, Mysliwiec M, De Gaetano G. 1977; b Prostacyclin and atherosclerosis in rats. Lancet 1: 1216
• 37 Willis AL, Vane FM, Kuhn DC, Scott CG, Petrin M. 1974; An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli: Purification, identification and unique biological significance. Prostaglandins 8: 453